Antisense startup Stoke Therapeutics secures another $90M in series B funding
Led by former Sarepta CEO, antisense startup Stoke Therapeutics has raked in $90 million in series B financing, following up the $40 million announced earlier this year.
Stoke licensed its technology, the so-called Targeted Augmentation of Nuclear Gene Output (TANGO), from Cold Spring Harbor Laboratory’s Adrian Krainer, who is credited as the inventor of Biogen’s $BIIB spinal muscular atrophy drug Spinraza. The $90 million in funding comes from RTW Investments with participation from founding investor Apple Tree Partners, that supplied the original $40 million injection in January.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.